Location History:
- Köln, DE (2015)
- Cologne, DE (1999 - 2021)
Company Filing History:
3 out of 9 
1 out of 601 
1 out of 44 
Years Active: 1999-2021
Title: Gudrun Schiedner: Innovator in Glycoprotein Research
Introduction
Gudrun Schiedner is a prominent inventor based in Cologne, Germany. She has made significant contributions to the field of glycoprotein research, holding a total of 6 patents. Her work focuses on enhancing the production and functionality of recombinant glycoproteins, which are crucial in various biotechnological applications.
Latest Patents
One of her latest patents is titled "Recombinant glycoproteins with reduced antennary fucosylation." This invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins. It also includes cell lines that can be utilized in these methods, along with respective recombinant glycoproteins and methods for expressing them in said cell lines. Another notable patent is "Method for the production of permanent human cell lines." This invention describes a permanent human cell line that comprises a nucleic acid sequence for the adenoviral gene functions E1A and E1B, as well as the nucleic acid sequence for the SV40 large T-antigen or the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1). Furthermore, it outlines a method for transient expression of recombinant polypeptides and proteins in this permanent human cell line.
Career Highlights
Throughout her career, Gudrun Schiedner has worked with notable organizations, including Cevec Pharmaceuticals GmbH and Baylor College of Medicine. Her expertise in glycoprotein research has positioned her as a key figure in the biotechnology sector.
Collaborations
She has collaborated with esteemed colleagues such as Christoph Volpers and Stefan Kochanek, contributing to advancements in her field.
Conclusion
Gudrun Schiedner's innovative work in glycoprotein research and her impressive portfolio of patents highlight her significant impact on biotechnology. Her contributions continue to influence the development of new therapeutic approaches and biotechnological advancements.